Pentoxifylline mitigates cholestasis-related cholemic nephropathy

Area of Science:

• Nephrology
• Hepatology
• Pharmacology

Background:

• Cholestasis, a condition of impaired bile flow, significantly impacts liver function and can lead to kidney injury, known as cholemic nephropathy (CN).
• Oxidative stress is a key factor in the development of cholemic nephropathy, yet effective pharmacological treatments remain limited.
• Pentoxifylline (PTX) has demonstrated renoprotective effects in various kidney injury models.

Purpose of the Study:

• To investigate the potential nephroprotective effects of pentoxifylline (PTX) in a rat model of cholestasis-induced kidney injury.
• To evaluate the impact of PTX on oxidative stress markers, inflammatory cytokine levels, and renal histopathology in cholestatic rats.

Main Methods:

• Bile duct ligation (BDL) was performed on rats to induce cholestasis.
• Rats were treated with varying doses of PTX (10, 50, and 100 mg/kg).
• Renal oxidative stress markers, urinary inflammatory cytokines (IL-1, IL-9, IL-18, TNF-α, INF-γ), and kidney histopathology were assessed.

Main Results:

• Bile duct ligation led to significant increases in oxidative stress markers and pro-inflammatory cytokines in renal tissue and urine.
• PTX treatment significantly ameliorated cholestasis-induced oxidative stress in the kidneys.
• PTX administration markedly improved renal histopathological alterations, including inflammation, tubular atrophy, fibrosis, and cast formation, and reduced elevated cytokine levels.

Conclusions:

• The findings suggest a significant nephroprotective role for pentoxifylline in cholestasis-induced kidney injury.
• PTX's renoprotective mechanisms are likely linked to its ability to mitigate oxidative stress and suppress the inflammatory response.
• PTX represents a potential therapeutic agent for managing cholemic nephropathy.